DISSECTING COX-1 RELATED GENE PATHWAYS IN OVARIAN CANCER
剖析卵巢癌中 COX-1 相关基因通路
基本信息
- 批准号:7561525
- 负责人:
- 金额:$ 14.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-01 至 2008-07-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseApoptosisBiological MarkersCause of DeathCell LineComputer Retrieval of Information on Scientific Projects DatabaseCustomDataDinoprostoneDiseaseEnzymesEtiologyFundingFutureGenesGoalsGrantHypoxiaImmunohistochemistryIn VitroInstitutionMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMeasuresMediatingMetabolismOvarianOvarian CarcinomaOvarian TissueOvulationPI3K/AKTPTGS2 genePathway interactionsProcessProductionProstaglandinsProto-Oncogene Proteins c-aktPublishingRangeResearchResearch PersonnelResourcesSignal TransductionSourceStaining methodStainsTissue MicroarrayTissue SampleUnited StatesUnited States National Institutes of HealthVascular Endothelial Growth Factorsabstractinganticancer researchbasecDNA Arrayscarcinogenesiscell growthcyclooxygenase 1inhibitor/antagonistmigrationresearch studytumor growthtumor progression
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Dissecting COX-1 Related Gene Pathways in Ovarian Cancer
ABSTRACT
Ovarian cancer is the leading cause of death among gynecologic cancers in the United States. The prostaglandin (PG) pathway mediated by cyclooxygenase-1 (COX-1) and the cycloogygenase-2 (COX-2) enzymes is implicated in ovulation and has been suggested as a potential factor in the etiology of ovarian cancer. Preliminary Data: We have utilized cDNA microarrays to compare normal ovarian tissue samples to ovarian carcinomas, and through this process have shown expression levels of COX-1 to be more than 2-fold higher in the cancers. Data published by our collaborators similarly demonstrates that COX-1, not COX-2, is highly expressed in ovarian malignancies. Hypothesis and Aims: The long-range goal of this research is to determine the specific contributions of COX-1 to ovarian carcinogenesis. We hypothesize that in ovarian cancers, COX-1 induces PGE2 production, which targets phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) signaling and components of this pathway that are involved in tumor growth and progression. We propose the use of custom-made tissue arrays for immunohistochemistry (IHC) staining to measure expression levels of COX-1, COX-2 and molecular markers associated with PI3K: phosphorylated AKT (pAKT), hypoxia induced factor (HIF-1a) and vascular endothelial growth factor (VEGF). Parallel in vitro experiments will be performed to further evaluate COX-1 function by treating a COX-1 expressing cell line, OVCAR3, with a selective COX-1 inhibitor, SC-560. We will measure PGE2 metabolism, cell growth, apoptosis, migration and invasion, as well as expression levels of PI3K, pAKT, HIF-1a and VEGF. We will also utilize cDNA microarrays to generate gene profiles that are associated with COX-1. Significance: If we determine that COX-1 is indeed a prominent factor in tumor progression in ovarian cancer, this research may provide the basis for its future use as a biomarker and target for therapy in the management of this deadly disease.
Specific Aims: The prostaglandin (PG) pathway mediated by cyclooxygenase-1 (COX-1 and cycloogygenase-2 (COX-2) enzymes is implicated in ovulation and has been suggested as a potential factor in the etiology of ovarian cancer. The long-range goal of this research is to determine the specific contributions of COX-1 to ovarian carcinogenesis.
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
卵巢癌中COX-1相关基因通路的剖析
摘要
卵巢癌是美国妇科癌症的主要死因。由环氧合酶-1(COX-1)和环氧合酶-2(COX-2)酶介导的前列腺素(PG)途径与排卵有关,并被认为是卵巢癌发病的潜在因素。初步数据:我们利用基因芯片对正常卵巢组织样本和卵巢癌样本进行了比较,通过这一过程显示COX-1在癌症中的表达水平高出2倍以上。我们的合作者发表的数据同样表明,在卵巢恶性肿瘤中高表达的是COX-1,而不是COX-2。假设和目的:本研究的长期目标是确定COX-1在卵巢癌发生中的具体作用。我们假设,在卵巢癌中,COX-1诱导PGE2的产生,PGE2的靶向是磷脂酰肌醇3激酶/蛋白激酶B(PI3K/AKT)信号和该途径中与肿瘤生长和进展有关的成分。我们建议使用定制的组织芯片免疫组织化学(IHC)染色来检测COX-1、COX-2的表达水平以及与PI3K相关的分子标志物:磷酸化AKT(PAKT)、缺氧诱导因子(HIF-1a)和血管内皮生长因子(VEGF)。通过选择性COX-1抑制剂SC-560处理表达COX-1的细胞系OVCAR3,将进行平行的体外实验,以进一步评估COX-1的功能。我们将检测PGE2代谢、细胞生长、凋亡、迁移和侵袭,以及PI3K、PAKT、HIF-1a和VEGF的表达水平。我们还将利用基因芯片来生成与COX-1相关的基因图谱。意义:如果我们确定COX-1确实是卵巢癌肿瘤进展中的一个重要因素,这项研究可能为未来将其用作生物标记物和治疗这一致命疾病的靶点提供基础。
目的:由环氧合酶-1(COX-1)和环氧合酶-2(COX-2)酶介导的前列腺素(PG)途径与排卵有关,并被认为是卵巢癌发病的潜在因素。这项研究的长期目标是确定COX-1在卵巢癌发生中的具体作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dineo Khabele其他文献
Dineo Khabele的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dineo Khabele', 18)}}的其他基金
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer
同源重组卵巢癌的表观遗传药物治疗方案
- 批准号:
10362606 - 财政年份:2020
- 资助金额:
$ 14.5万 - 项目类别:
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer
同源重组卵巢癌的表观遗传药物治疗方案
- 批准号:
10207160 - 财政年份:2020
- 资助金额:
$ 14.5万 - 项目类别:
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer
同源重组卵巢癌的表观遗传药物治疗方案
- 批准号:
10737850 - 财政年份:2020
- 资助金额:
$ 14.5万 - 项目类别:
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer
同源重组卵巢癌的表观遗传药物治疗方案
- 批准号:
10117210 - 财政年份:2020
- 资助金额:
$ 14.5万 - 项目类别:
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer
同源重组卵巢癌的表观遗传药物治疗方案
- 批准号:
10578788 - 财政年份:2020
- 资助金额:
$ 14.5万 - 项目类别:
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer - Diversity Supplement
用于同源重组熟练卵巢癌的表观遗传药物治疗方案 - Diversity Supplement
- 批准号:
10599719 - 财政年份:2020
- 资助金额:
$ 14.5万 - 项目类别:
SRI Meeting: Training and Development in the Reproductive Sciences
SRI 会议:生殖科学的培训和发展
- 批准号:
10609173 - 财政年份:2018
- 资助金额:
$ 14.5万 - 项目类别:
Targeting Cyclin E in Ovarian Cancer with Histone Deacetylase Inhibitors
使用组蛋白脱乙酰酶抑制剂靶向卵巢癌中的细胞周期蛋白 E
- 批准号:
9298005 - 财政年份:2017
- 资助金额:
$ 14.5万 - 项目类别:
Targeting Histone Deacetylases with Small Moleule Inhibitors in Ovarian Cancer
用小分子抑制剂靶向卵巢癌中的组蛋白脱乙酰酶
- 批准号:
8066414 - 财政年份:2010
- 资助金额:
$ 14.5万 - 项目类别:
Targeting Histone Deacetylases with Small Moleule Inhibitors in Ovarian Cancer
用小分子抑制剂靶向卵巢癌中的组蛋白脱乙酰酶
- 批准号:
8460917 - 财政年份:2010
- 资助金额:
$ 14.5万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 14.5万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 14.5万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 14.5万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 14.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 14.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 14.5万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 14.5万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 14.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 14.5万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 14.5万 - 项目类别:
Discovery Grants Program - Individual